Preventing oxaliplatin-induced neurotoxicity: rationale and design of phase Ib randomized, double-blind, placebo-controlled, cross-over trials for early clinical evaluation of investigational therapeutics

  • Catherine H. Han, Dean H. Kilfoyle, Andrew G. Hill, Michael B. Jameson, Mark J. McKeage
  • Expert Opinion on Drug Metabolism & Toxicology, August 2016, Taylor & Francis
  • DOI: 10.1080/17425255.2016.1223625

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1080/17425255.2016.1223625